Anna Ljung

Amministratore Delegato presso MOBERG PHARMA AB

Patrimonio netto: 1 971 $ in data 30/06/2024

44 anni

84 relazioni

Health Technology

Distribution Services

Consumer Services

Relazioni attive

Nome	Sesso	Età	Società collegate	Collaborazione
Jørgen Drejer	M	69	SANA AB Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	13 anni
Joseph deBethizy	M	74	SANA AB Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	5 anni
Thomas Feldthus	M	64	SANA AB Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	13 anni
Mattias Klintemar	M	57	BIOSERGEN AB ONCOZENGE AB MOBERG PHARMA AB	3 anni
Anita Milland	F	56	SANA AB	10 anni
Carl Johan Bertil Sundberg	M	66	SANA AB Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	9 anni
Palle Christophersen	M	66	SANA AB Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	13 anni
Rikard Akhtarzand	M	52	ADDVISE GROUP AB	16 anni
Pierandrea Muglia	M	58	SANA AB	1 anni
Kerstin Valinder-Strinnholm	F	64	MOBERG PHARMA AB	2 anni
Peder Andersen	M	72	BIOSERGEN AB	-
Nikolaj Sørensen	M	52	MOBERG PHARMA AB	3 anni
Erik Staffan Torstensson	M	52	ADDVISE GROUP AB	4 anni
Anders Lundmark	M	66	MOBERG PHARMA AB	2 anni
Lars Fredrik Celsing	M	57	ADDVISE GROUP AB	8 anni
Karin Nielsen	F	54	SANA AB	-
Markus Jerling	M	72	ONCOZENGE AB	3 anni
Håkan Wallin	M	62	MOBERG PHARMA AB	1 anni
Tine Kold Olesen	M	-	BIOSERGEN AB	-
Marianne Kock	F	69	BIOSERGEN AB	3 anni
Gunilla Wengström	F	62	MOBERG PHARMA AB	5 anni
Anders Bröijersén	M	60	MOBERG PHARMA AB	1 anni
Hanna Rebecca Lovisa Myhrman	F	32	ADDVISE GROUP AB	5 anni
Leila Malik	M	-	BIOSERGEN AB	-
Mark Beveridge	M	46	MOBERG PHARMA AB	9 anni
Anker Gunvald Lundemose	M	63	Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	-
Annica Magnusson	F	61	MOBERG PHARMA AB	5 anni
Johanne Louise Brændgaard	F	50	ADDVISE GROUP AB	3 anni
Leif Jan Eugen Andersson	M	67	Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	-
Janus Schreiber Larsen	M	52	SANA AB	-
Niels Laursen	M	68	BIOSERGEN AB	3 anni
Fredrik Mella	M	54	ADDVISE GROUP AB	2 anni
Rudolf Baumgartner	M	65	SANA AB	4 anni
Oliver Humlen	M	33	ADDVISE GROUP AB	1 anni

Mostra altro

Grafico relazionale

Relazione in diverse aziende

Relazioni precedenti

Nome	Sesso	Età	Società collegate	Collaborazione
Peter Gunnar Maurits Wolpert	M	55	MOBERG PHARMA AB	16 anni
Erland Pontusson	M	71	ADDVISE GROUP AB	9 anni
Thomas Lennart Eklund	M	57	MOBERG PHARMA AB	4 anni
Karl Fredrik Otto Granström	M	56	MOBERG PHARMA AB	16 anni
Mats Gunnar Pettersson	M	78	MOBERG PHARMA AB	6 anni
Achim Kaufhold	M	66	BIOSERGEN AB	3 anni
Thomas Bjerregaard Thomsen	M	55	MOBERG PHARMA AB	4 anni
Torbjörn Mattias Koivisto	M	55	MOBERG PHARMA AB	9 anni
Geert Cauwenbergh	M	70	MOBERG PHARMA AB	7 anni
Pirkko Sulila Tamsen	M	65	ONCOZENGE AB	3 anni
Gustaf Bertel Lindewald	M	82	MOBERG PHARMA AB	-
Torbjörn Wärnheim	M	66	MOBERG PHARMA AB	7 anni
Cindy Wong	M	65	MOBERG PHARMA AB ONCOZENGE AB	3 anni
Rami Levin	M	55	SANA AB	2 anni
Henrik Kristian Moltke	M	66	BIOSERGEN AB	3 anni
Wenche Nelly A. Rolfsen Sandsborg	M	72	MOBERG PHARMA AB	7 anni
Robert Hoffman	M	58	SANA AB	1 anni
Andrew B. Hochman	M	57	MOBERG PHARMA AB	-
Bengt Miller	M	-	ADDVISE GROUP AB	1 anni
Sebastian Robson	M	38	ADDVISE GROUP AB	1 anni
Marie Scherlund	M	58	MOBERG PHARMA AB	-
Jesper Lind	M	64	MOBERG PHARMA AB	-
Ingela Berglund	F	-	MOBERG PHARMA AB	-
Linea Aspesi	F	-	SANA AB	-
Denelle Waynick	F	57	SANA AB	-
Fredrik Netzel	M	55	MOBERG PHARMA AB	8 anni
Shaw Sorooshian	M	60	MOBERG PHARMA AB	2 anni
Wendy Dwyer	F	50	SANA AB	1 anni
Torben Mogensen	M	71	ONCOZENGE AB	3 anni
Sarah Hellerfelt	F	42	MOBERG PHARMA AB	2 anni
Kyle Haraldsen	M	-	SANA AB	-
Edward Saltzman	M	69	SANA AB	3 anni
Martin Ingman	M	62	MOBERG PHARMA AB	9 anni
Magnus Persson	M	60	MOBERG PHARMA AB	-
Kjell Rensfeldt	M	67	MOBERG PHARMA AB	11 anni
Anna Yvonne Monica Malm Bernsten	F	63	MOBERG PHARMA AB	1 anni
George Aitken-Davies	M	46	MOBERG PHARMA AB	2 anni
Trista Morrison	F	-	SANA AB	-
Lena Pereswetoff Morath	M	64	MOBERG PHARMA AB	-
Paul de Potocki	M	62	ONCOZENGE AB	2 anni
Marie Moberg	F	-	MOBERG PHARMA AB	-
Bengt Åke Ingemar Aldén	M	81	MOBERG PHARMA AB	-
Peter Michael Rothschild	M	74	MOBERG PHARMA AB	-
Ernst Åke Bertil Karlmark	M	86	MOBERG PHARMA AB	6 anni
Torsten Rüdiger Goesch	M	65	BIOSERGEN AB	9 anni
Jeff Vernimb	M	61	MOBERG PHARMA AB	2 anni
Jason Amello	M	55	SANA AB	2 anni
Sara Catherine Brandt	F	61	MOBERG PHARMA AB	2 anni
Hilde Furberg	F	65	ONCOZENGE AB	3 anni
Agneta Larhed	M	60	MOBERG PHARMA AB	-

Statistiche

Paese	Relazioni	% del totale
Svezia	63	75.00%
Danimarca	21	25.00%

Età delle relazioni

Attive

Scorse

Uomo

Donna

Amministratori

Dirigenti

Provenienza delle relazioni

Borsa valori
Insiders
Anna Ljung
Contatti personali